抗生素抗藥性市場規模、佔有率和成長分析（按疾病、病原體、藥物類別、病原體類型、作用機制、分銷管道和地區）- 2025-2032 年產業預測

2023 年全球抗生素抗藥性市場規模價值 101.6 億美元，預計將從 2024 年的 110.8 億美元成長到 2032 年的 222.5 億美元，預測期內（2025-2032 年）的複合年成長率為 9.1%。

由於人們對這一重大健康危機的擔憂日益加劇，並且影響了標準感染疾病治療的有效性，全球抗生素抗藥性市場正在經歷顯著成長。加劇這場危機的主要因素包括抗生素的過度使用、濫用以及醫療環境中的感染預防措施不足。此外，新抗生素的不斷減少也加劇了治療的限制。但政府、醫療保健相關人員和製藥公司越來越意識到，迫切需要應對這場危機。官民合作關係正在刺激抗生素開發的創新，抗生素管理計劃正在加強以最佳化使用。此外，教育措施也正在提高醫療保健專業人士和一般大眾的意識。基因組學和蛋白​​質組學的進展，加上噬菌體療法等新型治療方法，為有效解決抗生素抗藥性問題帶來了挑戰和機會。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

抗生素抗藥性市場規模（依疾病區分）

• 市場概況
• 複雜性尿道感染(cUTI)
• CDI（困難梭狀桿菌感染疾病）
• ABSSSI（急性細菌性皮膚和皮膚結構感染疾病）
• HABP（院內獲得性細菌性肺炎）
• CABP（社區型肺炎）
• cIAI（複雜性腹腔內感染疾病）
• BSI（血流感染疾病）

抗生素抗藥性市場規模（按病原體分類）

• 市場概況
• 大腸桿菌
• 肺炎克雷伯桿菌
• 銅綠假單胞菌
• 金黃色葡萄球菌

鮑曼

• 肺炎鏈球菌
• 流感 流感嗜血桿菌

艱難梭菌

• 屎腸球菌

抗生素抗藥性市場規模（依藥物類別）

• 市場概況
• Oxazolidinone
• 醣肽
• 四環黴素
• 聯合治療
• 頭孢菌素
• 其他

按病原體類型分類的抗生素抗藥性市場規模

• 市場概況
• 鮑氏靜止桿菌
• 銅綠假單胞菌
• 金黃色葡萄球菌
• 肺炎鏈球菌
• 其他

抗生素抗藥性市場規模（依作用機制分類）

• 市場概況
• 蛋白質合成抑制劑
• 細胞壁合成抑制劑
• RNA合成抑制劑
• DNA 合成抑制劑
• 其他

抗生素抗藥性市場規模（按分銷管道）

• 市場概況
• 醫院藥房
• 零售藥局
• 網路藥局

抗生素抗藥性市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• GlaxoSmithKline（GSK）（United Kingdom）
• Pfizer（United States）
• AbbVie（United States）
• Merck & Co.（United States）
• Johnson & Johnson（United States）
• Novartis（Switzerland）
• Roche（Switzerland）
• AstraZeneca（United Kingdom）
• Eli Lilly and Company（United States）
• Bristol-Myers Squibb（United States）
• Bayer AG（Germany）
• Takeda Pharmaceutical Company（Japan）
• Amgen（United States）
• Teva Pharmaceutical Industries（Israel）
• Abbott Laboratories（United States）
• Bausch Health（Canada）
• Vaxcyte（United States）
• Sumitomo Pharma（Japan）
• Fujifilm Holdings Corporation（Japan）

結論和建議

Global Antibiotic Resistance Market size was valued at USD 10.16 billion in 2023 and is poised to grow from USD 11.08 billion in 2024 to USD 22.25 billion by 2032, growing at a CAGR of 9.1% during the forecast period (2025-2032).

The global antibiotic resistance market is witnessing substantial growth due to escalating concerns surrounding this critical health crisis, which jeopardizes the efficacy of standard infectious disease treatments. Key factors fueling this crisis include antibiotic overuse, misuse, and insufficient infection prevention measures across healthcare settings. Additionally, the diminishing pipeline of new antibiotics exacerbates treatment limitations. However, an increasing acknowledgment among governments, healthcare entities, and pharmaceutical companies underscores the urgency to combat antibiotic resistance. Public-private partnerships are fostering innovation in antibiotic development, while antibiotic stewardship programs are being enhanced to optimize usage. Furthermore, educational initiatives are improving awareness among healthcare professionals and the public. Advancements in genomics and proteomics, alongside emerging treatments like phage therapy, present both challenges and opportunities in addressing antibiotic resistance effectively.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibiotic Resistance market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibiotic Resistance Market Segments Analysis

Global Antibiotic Resistance Market is segmented by Disease, Pathogen, Drug Class, Pathogen Type, Mechanism of Action, Distribution Channel and region. Based on Disease, the market is segmented into cUTI (Complicated Urinary Tract Infections), CDI (Clostridioides difficile Infection), ABSSSI (Acute bacterial skin and skin structure infections), HABP (Hospital-acquired bacterial pneumonia), CABP (Community-acquired pneumonia), cIAI (Complicated intra-abdominal infection) and BSI (Bloodstream infection). Based on Pathogen, the market is segmented into E. coli, K. pneumoniae, P. aeruginosa, S. aureus, A. baumannii, S. pneumoniae, H. influenzae, C. difficile and E. faecium. Based on Drug Class, the market is segmented into Oxazolidinones, Lipoglycopeptides, Tetracyclines, Combination therapies, Cephalosporins and Others. Based on Pathogen Type, the market is segmented into Acinetobacter Baumannii, Pseudomonas Aeruginosa, Staphylococcus Aureus, Streptococcus Pneumoniae and Others. Based on Mechanism of Action, the market is segmented into Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors, RNA Synthesis Inhibitors, DNA Synthesis Inhibitors and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antibiotic Resistance Market

The surge in infections caused by antibiotic-resistant bacteria underscores the urgent need for the creation of effective treatment solutions. As conventional antibiotics lose their efficacy, there is an increasing demand for novel antibiotics and alternative therapeutic strategies to tackle these resistant strains. This pressing need drives extensive research and development efforts in the field, resulting in the discovery of new drugs and innovative treatment methods to counter antibiotic resistance. Furthermore, the growing public awareness regarding the severe implications of antibiotic resistance has prompted governments, healthcare organizations, and pharmaceutical companies to dedicate resources and invest in initiatives designed to address this critical issue.

Restraints in the Global Antibiotic Resistance Market

The global market for antibiotics faces significant challenges due to the relatively sparse pipeline of new antibiotic candidates in the face of escalating antibiotic resistance threats. The intricate and demanding process of developing novel antibiotics necessitates substantial investment, time, and specialized knowledge. Factors like the exorbitant costs of research and development, regulatory hurdles, and unattractive returns on investment have led to a downturn in antibiotic innovation. This scarcity of new antibiotics impairs the effective treatment of antibiotic-resistant infections, highlighting the pressing need for enhanced initiatives and incentives to promote and accelerate the development of novel antibiotics in the healthcare sector.

Market Trends of the Global Antibiotic Resistance Market

The Global Antibiotic Resistance market is witnessing a significant trend towards the exploration of alternative treatment modalities, driven by the escalating challenge of antibiotic resistance. As conventional antibiotics become less effective, researchers and healthcare professionals are increasingly focusing on innovative solutions such as phage therapy. This cutting-edge approach utilizes bacteriophages to selectively target and eradicate antibiotic-resistant bacteria, effectively addressing the limitations of traditional antibiotics while preserving beneficial microbiota. The growing recognition of the potential of phage therapy, coupled with increased investment in research and development, is set to reshape the landscape of infection management, promising improved patient outcomes in the face of rising resistance.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Antibiotic Resistance Market Size by Disease & CAGR (2025-2032)

• Market Overview
• cUTI (Complicated Urinary Tract Infections)
• CDI (Clostridioides difficile Infection)
• ABSSSI (Acute bacterial skin and skin structure infections)
• HABP (Hospital-acquired bacterial pneumonia)
• CABP (Community-acquired pneumonia)
• cIAI (Complicated intra-abdominal infection)
• BSI (Bloodstream infection)

Global Antibiotic Resistance Market Size by Pathogen & CAGR (2025-2032)

• Market Overview
• E. coli
• K. pneumoniae
• P. aeruginosa
• S. aureus

baumannii

• S. pneumoniae
• H. influenzae

difficile

• E. faecium

Global Antibiotic Resistance Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Oxazolidinones
• Lipoglycopeptides
• Tetracyclines
• Combination therapies
• Cephalosporins
• Others

Global Antibiotic Resistance Market Size by Pathogen Type & CAGR (2025-2032)

• Market Overview
• Acinetobacter Baumannii
• Pseudomonas Aeruginosa
• Staphylococcus Aureus
• Streptococcus Pneumoniae
• Others

Global Antibiotic Resistance Market Size by Mechanism of Action & CAGR (2025-2032)

• Market Overview
• Protein Synthesis Inhibitors
• Cell Wall Synthesis Inhibitors
• RNA Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Others

Global Antibiotic Resistance Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Antibiotic Resistance Market Size & CAGR (2025-2032)

• North America (Disease, Pathogen, Drug Class, Pathogen Type, Mechanism of Action, Distribution Channel)
  • US
  • Canada
• Europe (Disease, Pathogen, Drug Class, Pathogen Type, Mechanism of Action, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease, Pathogen, Drug Class, Pathogen Type, Mechanism of Action, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease, Pathogen, Drug Class, Pathogen Type, Mechanism of Action, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease, Pathogen, Drug Class, Pathogen Type, Mechanism of Action, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• GlaxoSmithKline (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxcyte (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Pharma (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Holdings Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations